Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer

PUBLISHED Monday, April 27, 2026 · relay therapeutics, inc.

AI BRIEFING

⬤ Zovegalisib plus atirmociclib and AI combination approved for frontline metastatic breast cancer treatment, promising improved patient outcomes.
⬤ Clinical data supports further development of this triplet regimen in treating metastatic breast cancer.
⬤ Regimen's efficacy and safety profile warrants continued investigation in clinical trials.